GlassScriptPhysician profile
Samia Malik
NPI 1982022679
$7,903.96
in general payments reported to CMS, 2019-2025
34 companies · $1,688 in 2025
The $1,688 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $393 · 2021: $649 · 2022: $1,419 · 2023: $1,561 · 2024: $1,838 · 2025: $1,688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,087.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,086.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,514.17 | 2021-2025 | |
| Pfizer INC. | $1,153.49 | 2022-2025 | |
| Lilly USA, LLC | $505.25 | 2020-2025 | Kisunla, Amyvid, Emgality |
| Sk Life Science, INC. | $492.34 | 2020-2024 | Xcopri |
| Ucb, INC. | $422.92 | 2021-2025 | Briviact, Rystiggo |
| Catalyst Pharmaceuticals, INC. | $390.65 | 2023-2025 | Fycompa |
| Eisai INC. | $356.32 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $312.04 | 2022-2025 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $301.48 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $289.83 | 2022 | |
| Allergan, INC. | $287.48 | 2019-2021 | |
| Argenx US, INC. | $261.86 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Novartis Pharmaceuticals Corporation | $239.24 | 2020-2024 | |
| Celgene Corporation | $167.11 | 2022-2024 | Zeposia |
| Sunovion Pharmaceuticals INC. | $162.45 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $148.54 | 2022-2024 | Vyepti |
| Amneal Pharmaceuticals LLC | $143.78 | 2020-2022 | |
| Neurelis, INC. | $126.52 | 2020-2025 | Valtoco |
| C2n Diagnostics, LLC | $76.09 | 2025 | Precivityad2 |
| Collegium Pharmaceutical, INC. | $75.33 | 2022 | |
| Sumitomo Pharma America, INC. | $61.72 | 2023-2024 | Aptiom |
| Amgen INC. | $60.49 | 2021-2023 | Aimovig |
| Jazz Pharmaceuticals INC. | $59.30 | 2021-2023 | Xywav |
| Axsome Therapeutics, INC. | $48.50 | 2025 | Symbravo |
| Livanova USA, INC. | $44.14 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Genentech USA, INC. | $34.18 | 2025 | Ocrevus Zunovo |
| Ge Healthcare | $30.04 | 2025 | |
| Csl Behring | $22.15 | 2023 | Hizentra |
| Glaxosmithkline, LLC. | $21.36 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $20.21 | 2021 | |
| Cycle Pharmaceuticals INC | $19.96 | 2025 | Bafiertam, Tascenso Odt |
| Impel Pharmaceuticals INC. | $19.48 | 2022 | |
| Avanir Pharmaceuticals, INC. | $17.81 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $17.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samia Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.